Clinical Study
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
Table 4
Number of patients experiencing the most frequent treatment-related adverse events.
| | Grade 1 | Grade 2 | Grade 3 |
| Hematological | | | | Neutropenia | 19 (44.1%) | 14 (32.5%) | 8 (18.6%) | Anemia | 20 (46.5%) | 15 (34.8%) | 6 (13.9%) | Thrombocytopenia | 18 (41.8%) | 12 (27.9%) | 4 (9.3%) |
| Nonhematological | | | | Nausea/vomiting | 12 (27.9%) | 8 (18.6%) | 0 | Diarrhea | 9 (20.9%) | 6 (13.9%) | 0 | Constipation | 13 (30.2) | 11(25.5%) | 0 | Nail changes | 22 (51.1% ) | 17 (39.5%) | 2 (4.6%) | Dry eye/tearing | 26 (60.4%) | 15 (34.8%) | 0 | Myalgia/arthralgia | 22 (51.1%) | 14 (32.5%) | 0 | Fatigue | 21 (48.8%) | 18 (41.8%) | 2 (4.6%) | Sensory neuropathy | 16 (37.2%) | 7 (16.2%) | 0 | Peripheral edema | 22 (51.1%) | 8 (18.6%) | 0 | Epistaxis | 23 (53.4%) | 7 (16.2%) | 1 (2.3%) | Dyspnea | 12 (27.9%) | 5 (11.6%) | 0 |
|
|